Mavis Nye Foundation
  • Why a Foundation.
    • Updates Page 2
    • Legal Advice & Financial Assistance Help
    • Board of Trustee`s
    • Advisory Commitee
    • GDPR
  • Help and Support
  • Videos
    • Video page 2
    • Page 3
    • Page 4 videos
    • Page 5 Video
    • Page 6 videos >
      • Sound Bytes
    • Page 7 Videos >
      • ADAO Interview
    • Page 8
    • demolition Awards
    • Jennys Story
    • Podcast 147
    • Brendan
  • Current ACTIVE Supporters
    • Supporters
  • Contact Mavis
  • My Donate Page
  • Our Books
  • Peritoneal Mesothelioma
  • Mavis`s DNA REPORT
    • DNA Page 2
    • DNA Report Page 3
    • DNA Report Page 4
    • DNA Report Page 5
    • Dna Report page 6
  • Cancer Care Map
  • Asbestos Smart
  • National Cancer Institute
  • Report Fly Tipping
  • Most Influential
  • Living with Mesothelioma
  • HON DOCTORS
  • HSE PODCAST
  • Asbestomony
  • Breathless
  • UPDATES
  • Asbestos Report 2022
DNA Report page 4
Picture

Figure 4 Circos plot of CNA and somatic mutations. From outermost to innermost track: progression sample CNA (log2R), baseline sample CNA (log2R), progression sample mutations and baseline sample mutations. CNAs, copy number alterations. 

​

evidence suggests chemotherapy causes a degree of immune activation,9 and studies propose rational combination and sequencing of chemotherapy and CPI to achieve this end. The phase II DREAM study of durvalumab in combination with pemetrexed and cisplatin gave an objective treatment response rate of 48%, and a phase III is planned.10
The reduction in the number of somatic mutations between two samples can suggest subclones eliminated by pembrolizumab. This phenomenon is well described previously in patients with melanoma treated with nivolumab.11 On treatment with CPI, immunoediting 

​

occurs where tumor cells expressing neoantigens targeted by activated T cells are lost.12 The resulting loss of cancer heterogeneity results in more homogenous cancer cell population and a lower rate of somatic mutations and a lower TMB.
the case in context as a long-term responder to pembrolizumab and chemotherapy
What is remarkable about this patient’s initial response is the depth and duration. The relapse of disease occurred 21 months after the last dose of pembrolizumab. A recent paper suggests nivolumab can be detected more 

​
Picture
Pade 5
Proudly powered by Weebly